跳至主要内容
临床试验/ACTRN12620000259943
ACTRN12620000259943尚未招募未知

Assessing the performance of gluten immunogenic peptide (GIP) faecal assays after double-blind, single-dose gluten or placebo challenge in adults with treated coeliac disease

A/Professor Jason Tye-Din0 个研究点目标入组 50 人开始时间: 2020年2月27日最近更新:

试验速览

阶段
未知
状态
尚未招募
发起方
入组人数
50

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Diagnosis
盲法
Blinded (masking used)

入排标准

年龄范围
18 Years 至 70 Years(—)
性别
All

入选标准

  • Adults 18 up to 70 years of age including males and females.
  • A diagnosis of coeliac disease based on consensus criteria (positive coeliac serology and typical small intestinal enteropathy at diagnosis), and following a strict gluten free diet for at least 12 months with negative coeliac serology and normal Celiac Dietary Adherence Test (CDAT) at baseline.
  • Faecal samples from coeliac or non-coeliac (healthy) participants not following a gluten free diet will also be collected and serve as positive controls for the faecal assay.

排除标准

  • Inability to give informed consent, understand English, or suffering from a medical condition that the investigator believes may affect the safe conduct of the trial or complicate interpretation of results.

研究者

发起方
A/Professor Jason Tye-Din

相似试验